Sensei Biotherapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Hello, everyone. Thank you for your time and attention today. I'm very happy to present to you Sensei Bio's conditionally active antibodies for immuno-oncology. But first, I just want to thank Oppenheimer for inviting us to the conference and for their continued support. Oppenheimer played an important role in Sensei Bio's IPO two years ago.
As you can see from our cover slide, we are an immuno-oncology company developing conditionally active antibodies. And we're going to talk about what conditionally active antibodies are throughout the presentation.
But before I get started, I will be making forward-looking statements here today, and this is our disclaimer.
Now, at Sensei Bio, we're particularly focused on one of the key challenges in immuno-oncology, and that is that many antibodies fail because of off-tumor binding. Systemically delivered immuno-oncology drugs are developed in a fairly canonical way and are developed to bind to targets both in the tumor and in the periphery. And this creates, in our view,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |